Aberdeen Group plc Acquires New Position in GeneDx Holdings Corp. $WGS

Key Points

• Aberdeen Group plc has acquired a new stake in GeneDx Holdings Corp., purchasing 136,732 shares valued at approximately $12.6 million, representing about 0.48% of the company.
• GeneDx reported $0.50 earnings per share (EPS) for the last quarter, exceeding analysts' estimates of $0.10, with revenues of $102.69 million.
• Analysts have varied ratings for GeneDx with a consensus rating of "Moderate Buy" and an average price target of $104.13.

Aberdeen Group plc acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 136,732 shares of the company's stock, valued at approximately $12,622,000. Aberdeen Group plc owned about 0.48% of GeneDx as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in GeneDx by 151.7% during the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after purchasing an additional 264 shares during the last quarter. US Bancorp DE grew its position in GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after purchasing an additional 548 shares during the last quarter. KBC Group NV purchased a new stake in GeneDx during the 1st quarter valued at about $81,000. PNC Financial Services Group Inc. purchased a new stake in GeneDx during the 1st quarter valued at about $132,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in GeneDx by 184.8% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,224 shares of the company's stock valued at $197,000 after purchasing an additional 1,443 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Stock Performance

WGS opened at $116.91 on Thursday. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.19. The company has a market cap of $3.36 billion, a price-to-earnings ratio of 2,338.20 and a beta of 1.98. The company's 50 day moving average is $122.17 and its 200 day moving average is $95.76. GeneDx Holdings Corp. has a 12-month low of $54.14 and a 12-month high of $136.00.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.40. The company had revenue of $102.69 million for the quarter, compared to the consensus estimate of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. On average, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Insider Buying and Selling at GeneDx

In related news, Director Jason Ryan sold 38,072 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the transaction, the director owned 103,284 shares of the company's stock, valued at approximately $13,148,053.20. This trade represents a 26.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Katherine Stueland sold 10,501 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $1,275,556.47. Following the completion of the transaction, the chief executive officer directly owned 14,578 shares in the company, valued at approximately $1,770,789.66. The trade was a 41.87% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 556,371 shares of company stock worth $67,489,314. 29.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Piper Sandler lifted their price target on shares of GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, September 11th. Guggenheim reiterated a "buy" rating and issued a $115.00 price target (up from $88.00) on shares of GeneDx in a research note on Monday, June 30th. Wells Fargo & Company lifted their price target on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $104.13.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.